The IgA nephropathy disease treatment market is projected to grow at a CAGR of XX.XX% to reach US$XX.XXX billion by 2024, from US$XX.XXX billion in 2018. The rising number of cases diagnosed with kidney diseases every year is one of the major drivers driving the growth of the global IgA nephropathy disease treatment market during the forecast period. The United States from the North American region is expected to hold a major market share. The disease is one of the main causes of acute nephritis among young people here. However, high disease prevalence is in the Asia Pacific region. IgA nephropathy is an autoimmune disorder also known as Berger’s disease when there is an accumulation of immunoglobulin A (IgA) in the kidneys. However, the actual cause is unknown. The disease is primarily asymptomatic and can be detected via routine tests only. Growing interests regarding the better understanding of the disease pathogenesis and non-availability of specific treatment are driving the market growth in the forecast period. Furthermore, growing health awareness will drive market growth owing to early disease detection in the coming years and beyond.
This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the IgA nephropathy disease treatment value chain. The last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the IgA nephropathy disease treatment market.
Major industry players profiled as part of the report are Retrophin, Inc., Calliditas Therapeutics AB, Alexion Pharmaceuticals, Inc. and Mallinckrodt Pharmaceuticals among others.
The IgA nephropathy disease treatment market has been analyzed through following segments:
Iothalamate clearance test
Lifestyle and home remedies
Middle East and Africa
Key insights offered
What will be the IgA nephropathy disease treatment market size from 2018 to 2024?
How are the major drivers and restraints affecting the IgA nephropathy disease treatment market growth and the opportunities which exist for key vendors?
Which segment and region will drive or lead the market growth and why?
A comprehensive analysis of competitive landscape and key market participants’ behaviour
Key strategies being adopted by vendors, with in-depth analysis along with their impact on competition and market growth.